2026. Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s738. DOI:https://doi.org/10.25251/0bwr4a20.